Mosaic Diagnostics, a leading provider of specialty diagnostics, is proud to announce the appointment of Scott Mattivi as its new Chief Executive Officer. With more than three decades of experience in the laboratory and biopharma services industry, Mattivi brings a proven track record of operational excellence, innovation, and strategic leadership.
“It’s an incredible honor to join Mosaic Diagnostics as CEO,” said Mattivi. “Mosaic pioneered the integrative health category and I’m truly humbled to join them at this stage of the company’s growth. Supporting practitioners on the front lines as they navigate complex and challenging diagnoses, for their patients, is profoundly rewarding. By equipping them with the tools and insights they need, we help improve patient outcomes and enhance quality of life. I am excited to collaborate with Mosaic’s talented team to build on its strong foundation and drive meaningful growth in the rapidly expanding field of integrative medicine.”
Mattivi most recently served as Chief Operations Officer at PathologyWatch, where he oversaw operations across multiple laboratories specializing in digital pathology services. Under his leadership, the organization achieved significant advancements in operational efficiency and quality assurance, further solidifying its position as an industry leader.
Prior to his tenure at PathologyWatch, Mattivi held leadership roles at Eurofins-Viracor BioPharma Services, where he drove substantial growth and innovation over 13 years, and at Quest Diagnostics, where he managed laboratory operations for over two decades. His deep expertise in clinical laboratory sciences and his commitment to operational excellence have made him a trusted leader in the diagnostics industry.
“Scott’s extensive experience and visionary leadership make him the ideal CEO to drive Mosaic Diagnostics into our next chapter of innovation and growth,” said Scott Cramer, Chairman of the Board at Mosaic Diagnostics. “His track record of driving lab innovation coupled with scaling organizations while maintaining a strong focus on patient outcomes aligns perfectly with our mission to provide clarity and solutions for complex chronic conditions. We are confident Scott will continue to elevate Mosaic in this exciting and rapidly growing market.”
